We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mirdametinib is an investigational mitogen-activated ...
GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...
CNW/ - Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Koselugo’s approval was based on data from the phase 3 ...
Neurofibromatosis type 1 (NF1) is a genetically inherited disorder that manifests in a broad spectrum of clinical features including dermatological, neurological, skeletal and notably, ocular ...
Twenty-four of 58 adults (41%) and 29 of 56 children (52%) had a BICR-confirmed objective response during the 24-cycle treatment phase; in addition, two adults and one child had confirmed responses ...
The FDA has approved selumetinib (Koselugo, AstraZeneca) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Selumetinib, an oral kinase ...
The US Food and Drug Administration (FDA) has approved mirdametinib (Gomekli, SpringWorks Therapeutics, Inc.) for certain adult and pediatric patients with neurofibromatosis type 1 (NF1). Specifically ...
RECKGIST score effectively predicts recurrence in neurofibromatosis type 1-associated GISTs, especially for tumors under 30 mm. Larger GISTs (over 30 mm) have a higher risk of metastasis, with ...
Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed. Overall, 53 ...
The FDA on Tuesday approved mirdametinib (Gomekli) for adults and kids ages 2 and up with neurofibromatosis type 1 (NF1). Approval of the MEK inhibitor is specifically for patients who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results